BioCentury
ARTICLE | Finance

Build-to-buy basket

GSK, Avalon Ventures double their build-to-buy portfolio to six start-ups

June 22, 2015 7:00 AM UTC

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Avalon Ventures doubled the number of build-to-buys in their deal to six, including the first build-to-buy that is homegrown by the VC.

The newest cohort of companies includes Adrenergics Inc., CadheRx Therapeutics Inc. and Calporta Therapeutics Inc. ...